Piper Sandler analyst Biren Amin assumed coverage of Kalaris Therapeutics (KLRS) with a Neutral rating and $3 price target The firm says the preclinical data for the company’s anti-VEGF, TH103, do not offer differentiation when compared to the standard of care in retinal diseases. Piper is on the sidelines pending better clarity on TH103’s clinical profile.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KLRS: